Gonococcal Isolate Surveillance Project (GISP)
The Gonococcal Isolate Surveillance Project (GISP) was established nationally in 1986 to monitor trends in antimicrobial susceptibilities of strains of N. gonorrhoeae in the United States in order to establish a basis for the selection of gonococcal therapies. The health impact of gonorrhea is largely related to its role as a major cause of pelvic inflammatory disease, which frequently leads to infertility or ectopic pregnancy. In addition, data suggest that gonorrhea can increase the chance of HIV transmission.
The treatment and control of gonorrhea has been complicated by the ability of bacteria to develop resistance to antimicrobial agents (antibiotics). The appearance of penicillin and tetracycline-resistant gonorrhea in the 1970s eventually led to the abandonment of these drugs as therapies for gonorrhea.
At regional laboratories throughout the United States, the susceptibilities of the gonorrhea bacteria to penicillin, tetracycline, spectinomycin, ciprofloxacin, ceftriaxone, cefixime, and azithromycin are determined. All states are creating their own preparedness plans for continued antimicrobial resistance to gonorrhea, since there are no new treatments on the horizon.
For more information about the Gonococcal Isolate Surveillance Project go to: www.cdc.gov/std/gisp/